Dr. Reddy's Laboratories (RDY) intends to launch a generic version of Novo Nordisk's (NVO) Ozempic this month in Canada, Bloomberg reported Tuesday, citing comments by Chief Executive Erez Israeli.
Health Canada approved its application in April, while exclusivity on semaglutide, the key ingredient in Ozempic and Wegovy, expired on Jan. 4 in Canada, the report said.
Dr. Reddy's didn't immediately reply to a request for comment from.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: $12.29, Change: $-0.86, Percent Change: -6.51%